سعر سيفوتريكس 500 مجم فيال وريد 2022

Cefotrix 500 mg i.v. vial (u.s.p.23): Ceftriaxone (T3a pharma).

• Parenteral third-generation cephalosporin for susceptible infections including lower respiratory tract, skin/skin structure, urinary tract, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia, bone and joint, intra-abdominal, meningitis, and surgical prophylaxis as labeled (US ceftriaxone injectable labeling).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Contraindicated with known hypersensitivity to ceftriaxone, its excipients, or other cephalosporins; do not use in hyperbilirubinemic neonates or concurrent IV calcium in neonates as labeled (US labels).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Serious hypersensitivity reactions; C. difficile–associated diarrhea; gallbladder sludge/pseudolithiasis; hemolytic anemia; coagulation abnormalities; do not mix/co-administer with calcium-containing IV solutions (US labels).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Calcium-containing IV solutionsPrecipitation risk; do not co-administer, especially in neonates (US labels).DailyMed (U.S. National Library of Medicine)
• AminoglycosidesPossible additive nephrotoxicity/ototoxicity; monitor as clinically indicated.DailyMed (U.S. National Library of Medicine)

• Available data have not established a drug-associated risk of major birth defects; use during pregnancy only if clearly needed (US ceftriaxone labels).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Present in human milk in low concentrations; developmental and health benefits of breastfeeding should be considered with clinical need (US labels).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Ceftriaxone: Long-acting third-generation cephalosporin inhibiting cell-wall synthesis via PBP binding; once-daily dosing common.